海思科：HSK39297片新适应症药物临床试验获批准

Core Viewpoint - The company, Haizhi Science (002653), has received approval from the National Medical Products Administration for a clinical trial of its drug HSK39297, which is indicated for generalized myasthenia gravis [1] Group 1 - The drug HSK39297 is specifically designed for the treatment of generalized myasthenia gravis [1] - The approval notification was issued by the National Medical Products Administration's review center [1]